Translation of "used vehicle information package " (English → French) :

Goods and Services Tax: Information for Dealers in Used Vehicles [ Information for Dealers in Used Vehicles ]

Used Vehicle Information Program

Protocol required by Article 8 (1) (e) (ii) of the Convention for the Establishment of a European Organisation for the Development and Construction of Space Vehicle Launchers, concerning the use of technical information for purposes not within the field of space technology

EUROPA - EU law and publications - EUR-Lex - EUR-Lex - 32008R0692 - EN - Commission Regulation (EC) No 692/2008 of 18 July 2008 implementing and amending Regulation (EC) No 715/2007 of the European Parliament and of the Council on type-approval of motor vehicles with respect to emissions from light passenger and commercial vehicles (Euro 5 and Euro 6) and on access to vehicle repair and maintenance information (Text with EEA relevance) - COMMISSION REGULATION - (EC) No 692/2008 // of 18 July 2008 // implementing and amending Regulatio ...[+++]n (EC) No 715/2007 of the European Parliament and of the Council on type-approval of motor vehicles with respect to emissions from light passenger and commercial vehicles (Euro 5 and Euro 6) and on access to vehicle repair and maintenance information // ADMINISTRATIVE PROVISIONS FOR EC TYPE-APPROVAL // Appendix 1 // Verification of conformity of production — First statistical method // Appendix 2 // Verification of conformity of production — Second statistical method // Appendix 3 // MODEL // INFORMATION DOCUMENT No . // Appendix to information document // INFORMATION ON TEST CONDITIONS // Appendix 4 // MODEL OF EC TYPE-APPROVAL CERTIFICATE // (Maximum format: A4 (210 × 297 mm)) // Addendum to EC type-approval certificate No . // concerning the type-approval of a vehicle with regard to emissions and access to vehicle repair and maintenance information according to Regulation (EC) No 715/2007 // Appendix 5 // Vehicle OBD information // Appendix 6 // EC Type –Approval Certification Numbering System // Appendix 7 // IN-SERVICE CONFORMITY // IN-SERVICE CONFORMITY CHECK // STATISTICAL PROCEDURE FOR IN-SERVICE CONFORMITY TESTING // RESPONSIBILITIES FOR IN-SERVICE CONFORMITY // VERIFYING AVERAGE EXHAUST EMISSIONS AT AMBIENT CONDITIONS // (TYPE 1 TEST) // EMISSIONS DATA REQUIRED AT TYPE-APPROVAL FOR ROADWORTHINESS PURPOSES // MEASURING CARBON MONOXIDE EMISSION AT IDLING SPEEDS // (TYPE 2 TEST) // MEASUREMENT OF SMOKE OPACITY // VERIFYING EMISSI ...

When a type 1 test is to be carried out for a vehicle type-approval that has one or several extensions, the type 1 tests shall be carried out either on the vehicle described in the initial information package or on the vehicle described in the information package relating to the relevant extension.

4.3.1. If a vehicle type has had one or several extensions, the tests shall be carried out on the vehicle(s) described in the information package which accompanied the first type-approval application, or on the vehicle described in the information package that accompanied the relevant extension.

With reference to the side effects experienced by those taking the anti-malarial drug mefloquine (Lariam): (a) provide a detailed update on the clinical study of mefloquine (Lariam) announced by the Department of National Defence in 1997, including trial design, subject inclusion/exclusion criteria, numbers of study subjects recruited to date and participating centres; (b) have reviews been undertaken of the side effects experienced by the Australian, British and Dutch forces, if so what were the results and recommendations, and what steps have been undertaken to implement these recommendations; (c) with regard to the mefloquine (Lariam) used for the prophylaxis ...[+++] of Canadian troops deployed to Somalia, what was the nature of the Department of Health's Health Protection Branch investigations in October 1997 into the failure of the manufacturer to properly supervise and ensure compliance with the Lariam safety monitoring study and the failure of the Department of National Defence to comply with its obligations under the safety monitoring study; (d) with regard to the mefloquine (Lariam) used for the prophylaxis of Canadian troops deployed to Somalia, what was the outcome of the Department of Health's Health Protection Branch investigations in October 1997 into the failure of the manufacturer to properly supervise and ensure compliance with the Lariam safety monitoring study and the failure of the Department of National Defence to comply with its obligations under the safety monitoring study; (e) what is the date of the insert in the mefloquine (Lariam) package used in Canada today; (f) what is the date of the product monograph for mefloquine (Lariam) used in Canada today; (g) have reviews been undertaken of the insert in the mefloquine (Lariam) package and the prescribing information used in Australia, if so what were the results and recommendations of the reviews, and what steps have been taken to implement the recommendations; (h) have reviews been undertaken ...